Upgraded revenue and earnings guidance

16 March 2020

Upgraded revenue and earnings guidance
Blis Technologies (NZX:BLT) announced today that it has upgraded its revenue and earnings guidance
for the financial year ended 31 March 2020.
Guidance provided in February was for revenue in excess of $9.4m and EBITDA in excess of $1.0m.
The company expects full year revenue of around $10.0m and EBITDA of between $1.5m to $1.7m,
subject to completion of existing orders and audit.
Sharp increases in sales of our BLIS
TM
finished goods are complementing a strong year of sales of our
branded ingredients into international markets. Additionally, a portion of scheduled project
expenditure has been deferred to next financial year due to delays caused by the impacts of COVID-
19.
Brian Watson, CEO said, “Sales of our BLIS probiotic brands through pharmacies and online channels
in February and March were better than expected. This increase is across the Blis range but is
particularly evident for our products with an immune boosting proposition. BLIS TravelProtect
TM
,
UltraBLIS
TM
, DailyDefence
TM
and ThroatGuard PRO
TM
have all seen a lift in sales over this period.”
“We have noted media reports of immunity products seeing a lift in demand globally and it appears
some of our current increased sales are related to COVID-19 concerns. We believe consumers are
looking for products that may help support natural immunity.” “To date our supply chain, from
ingredient supply through to manufacture of finished product has been able to meet the lift in
demand and we have significantly increased our production to meet anticipated forward orders. We
continue to monitor our supply chain for any future constraints.”
Results for the 12 months to 31 March 2020 are expected to be announced in late May.

Ends

For further information, please contact:

Brian Watson
CEO
+64 27 705 9133

Blis Technologies Limited: 81 Glasgow Street, South Dunedin 9012, PO Box 2208, Dunedin 9012, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz
About Blis Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics
Blis is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation
with evidence-based research and the highest quality production controls enables the delivery of probiotic
solutions for specific health targets including throat health, halitosis (bad breath), immune support and teeth and
gum health. BLIS products are sold throughout New Zealand and in Australia, Asia, Europe and the USA. More
information about Blis Technologies Ltd can be found at www.blis.co.nz.

About UltraBLIS
TM

UltraBLIS is a next generation probiotic supplement targeted at those wanting to optimise their microbiome and
strengthen overall immunity. BLIS K12 has strong evidence in the oral microbiome, and it has been combined in a
lozenge format with Bifidobacterium lactis HN019 (HOWARU®), and Lactobacillus acidophilus La-14: 2 strains
from Dupont® that have strong evidence bases in immunity. More information about UltraBLIS
TM
can be found at
www.blis.co.nz/pages/ultrablis